Showing 4941-4950 of 5254 results for "".
- KYTHERA Biopharmaceuticals to Present at 32nd Annual J.P. Morgan Healthcare Conferencehttps://practicaldermatology.com/news/20140107-kythera_biopharmaceuticals_to_present_at_32nd_annual_jp_morgan_healthcare_conference/2459378/KYTHERA Biopharmaceuticals, Inc. (Nasdaq:KYTH) today announced that Keith Leonard, president and chief executive officer, will present at the 32nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA.
- Suneva Medical Announces 12-Month Safety Results From Artefill® Acne Scar Studyhttps://practicaldermatology.com/news/20140107-suneva_medical_announces_12-month_safety_results_from_artefill_acne_scar_study/2459379/Suneva Medical Inc. announced the 12-month follow-up data from its randomized, double-blinded, multi-center, Pivotal acne scar investigational study evaluating the safety and efficacy of ArteFillâ, a dermal filler, to treat acne scars.
- Wrinkle remover Revance files for $86 million IPOhttps://practicaldermatology.com/news/20140106-wrinkle_remover_revance_files_for_86_million_ipo/2459380/Revance Therapeutics Inc., a developer of next-generation versions of skin wrinkle eraser Botox, is seeking $86.25 million in an initial public offering.
- Promius Pharma®, LLC Introduces Isotretinoin Indigent Patient Assistance Programhttps://practicaldermatology.com/news/20140106-promius_pharma_llc_introduces_isotretinoin_indigent_patient_assistance_program/2459381/Promius Pharma is introducing a Promius Promise Patient Assistance Program for eligible patients who are uninsured, or whose insurance company does not provide coverage of isotretinoin and who otherwise meet program eligibility requirements. This program, which is integrated into the Promius Promise
- NeXeption, LLC Forms New Company Alexar Therapeutics, Inc. to Develop Novel LXR Agonist Portfolio for Dermatologic Indicationshttps://practicaldermatology.com/news/20140102-nexeption_llc_forms_new_company_alexar_therapeutics_inc_to_develop_novel_lxr_agonist_portfolio_for_dermatologic_indications/2459383/NeXeption, LLC, a biopharmaceutical management company that brings together product opportunities, management expertise and funding to reach compelling partnership milestones, has secured $21.5 million in Series A financing to form Alexar Therapeutic
- CSF 2013 Honors Top Resident Presentershttps://practicaldermatology.com/news/20131219-csf_2013_honors_top_resident_presenters/2459388/Nine residents have been recognized for their presentations at Cosmetic Surgery Forum 2013 held earlier this month. From a panel of residents who presented their research on a range of medical and cosmetic dermatology topics, the top
- Theradome Laser Helmet Launches for At-home Treatment of Hair Losshttps://practicaldermatology.com/news/20131219-theradome_laser_helmet_launches_for_at-home_treatment_of_hair_loss/2459389/Theradome Laser Helmet LH80 PRO, the first FDA and over-the-counter cleared, wearable laser hair restoration treatment, is now available. Developed for in-home use and designed for patients suffering from the effects of thinning hair and Androge
- Cynosure Announces Successful Settlement of Patent Infringement Lawsuitshttps://practicaldermatology.com/news/20131217-cynosure_announces_successful_settlement_of_patent_infringement_lawsuits/2459393/Cynosure, Inc. will receive $10 million plus future royalty payments under a comprehensive settlement agreement with Tria Beauty, Inc. that ends the patent infringement litigation between Tria and Palomar Medical Technologies, which
- Valeant Pharmaceuticals to Acquire Solta Medicalhttps://practicaldermatology.com/news/20131216-valeant_pharmaceuticals_to_acquire_solta_medical/2459394/Valeant Pharmaceuticals International, Inc. announced that it has entered into a definitive agreement to acquire all of the outstanding common stock
- Cosmetic Surgery Forum Kicks Off in Las Vegashttps://practicaldermatology.com/news/20131206-cosmetic_surgery_forum_kicks_off_in_las_vegas/2459397/The fifth annual Cosmetic Surgery Forum got underway yesterday in Las Vegas, Nevada, highlighted by varied educational sessions and discussion among faculty, attendees, and residents. Among the offerings from the first day were 75 resident presentations, practice management pearls, live injections,